StockData
Starling Oncology, Inc. logo

Starling Oncology, Inc. (STLN) stock

STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$3.40−0.14 (-3.95%)

Close on Nov 17, 2026Market cap $346.52MP/E –Yield –

Starling Oncology pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Starling Oncology's pe ratio was 245.8× on Apr 28, 2023.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Apr 28, 2023245.8×+126.8
2022Dec 30, 2022119.0×–

More Starling Oncology figures

See a number that looks wrong?